Gelesis is a registrational-stage biotechnology company developing a novel category of first-in-class therapies for weight loss and GI-related diseases. Our platform uses a clinically validated hydrogel technology composed of naturally derived building blocks.
The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Idiopathic Constipation (CIC).
Gelesis is headquartered in Boston, Mass. and was founded by PureTech Health and a group of leading obesity researchers. Gelesis is led by a strong management team, with expertise in medicine, materials science, manufacturing and commercialization. Our scientific advisory board and clinical advisors are leading experts in obesity and chronic disease.
Community guidelines: http://bit.ly/2Q8VfUG